A Timeline of Symptom Onset and Disease Progression in CLN3 Disease

ABSTRACT Background CLN3 disease, or Juvenile Neuronal Ceroid Lipofuscinosis (JNCL), is a rare, genetic neurodegenerative condition, typically manifesting in the first decade of life and progressing in severity, with death typically occurring in early adulthood. Despite two decades of natural history research, a clear timeline of CLN3 disease symptom onset and progression remains poorly defined, limiting optimal patient management and therapeutic development. We conducted a literature review and analysed the natural history data to better understand the age of core symptom onset and chronological disease progression. Methods A literature review was undertaken using a pre-defined search strategy focused on CLN3 disease natural history studies, where age at onset for one or more core symptoms was reported in cohorts of ≥15 subjects. For each symptom, weighted mean age at onset and weighted standard deviation were calculated, with 95% confidence intervals derived from the weighted standard error. Symptom onset ages were compared using ANOVA. Results We identified nine natural history studies that met our pre-defined criteria. In total, 423 discrete patients aged between 4 and 39 years were reported. Thirteen core symptoms and a weighted average age at onset and weighted standard deviation were (in years): vision loss (6.1 ± 1.6, N=254), behavioural changes (8.5 ± 3.9, N=194), cognitive decline (9.3 ± 3.1, N=219), seizures (10.2 ± 3.0, N=243), sleep disturbance (11.0 ± 6.1, N=111), motor decline (11.0 ± 3.8, N=108), complete blindness (11.4 ± 3.6, N=171), speech and language impairment (12.7 ± 4.8, N=136), Parkinsonian gait (14.1 ± 2.5, N=111), cardiac manifestations (17.8 ± 4.4, N=45), loss of independent walking (19.5 ± 3.2, N=70), feeding difficulties requiring enteral feeding tube (22.0 ± 1.6, N=35), and death (22.4 ± 4.4, N=95). Conclusion This comprehensive summary of available natural history data illustrates mean age at onset of 13 core symptoms of CLN3 disease, and characterises a chronological timeline of disease progression. These results provide much-needed practical, anticipatory guidance to those involved in caring for individuals with CLN3 disease, and serve to highlight the critical importance of collecting globally standardised, quantifiable, longitudinal data for optimising patient management and advancing therapeutic approaches for CLN3 disease.